For the quarter ended September 2025, Bristol Myers Squibb (BMY) reported revenue of $12.22 billion, up 2.8% over the same period last year. EPS came in at $1.63, compared to $1.80 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $11.83 billion, representing a surprise of +3.33%. The company delivered an EPS surprise of +10.14%, with the consensus EPS estimate being $1.48.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Bristol Myers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales- Cobenfy- Worldwide: $43 million versus the five-analyst average estimate of $40.86 million.
- Net Sales- Opdivo Qvantig- Worldwide: $67 million versus the five-analyst average estimate of $61.29 million.
- Net Sales- Opdivo Qvantig- U.S: $60 million versus $60.62 million estimated by four analysts on average.
- Net Sales- Pomalyst/Imnovid- U.S.: $596 million versus the four-analyst average estimate of $573.19 million. The reported number represents a year-over-year change of -14.5%.
- Net Sales- Orencia: $964 million compared to the $937.09 million average estimate based on five analysts. The reported number represents a change of +3% year over year.
- Net sales- Krazati- Worldwide: $53 million versus $55.94 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +55.9% change.
- Net Sales- Sotyktu: $80 million versus $75.52 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.2% change.
- Net Sales- Camzyos: $296 million versus the five-analyst average estimate of $246.45 million. The reported number represents a year-over-year change of +89.7%.
- Net Sales- Sprycel: $119 million versus $80.24 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -59% change.
- Net Sales- Yervoy: $739 million compared to the $691.44 million average estimate based on five analysts. The reported number represents a change of +15.1% year over year.
- Net Sales- Eliquis: $3.75 billion compared to the $3.61 billion average estimate based on five analysts. The reported number represents a change of +24.8% year over year.
- Net Sales- Opdivo: $2.53 billion compared to the $2.43 billion average estimate based on five analysts. The reported number represents a change of +7.3% year over year.
View all Key Company Metrics for Bristol Myers here>>>
Shares of Bristol Myers have returned -10.2% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
